Advertisement

Some antibody treatments won't work for COVID-19 variants, FDA says

Monoclonal antibodies are lab-engineered immune system proteins that are infused into patients to try to boost their immune response early in infections and sometimes try to prevent infection.

Advertisement

The U.S. Food and Drug Administration says two of Eli Lilly's coronavirus antibody treatments may not work against some of the new variants.

Monoclonal antibodies are lab-engineered immune system proteins that are infused into patients to try to boost their immune response early in infections and sometimes try to prevent infection.

The FDA reviewed research on the mutation characteristics of several new COVID-19 variants.

Although none of the experiments involved live, infected patients, the FDA said the findings could be serious enough to warrant revisions to emergency use authorizations for some treatments.

The FDA also said the dual antibody treatment from Regeneron Pharmaceuticals appears to be effective for protecting people against all of the variants worrying scientists the most.